EP1141278B1 - Inhibiteurs de la phosphodiesterase pde4d utilises a des fins therapeutiques - Google Patents

Inhibiteurs de la phosphodiesterase pde4d utilises a des fins therapeutiques Download PDF

Info

Publication number
EP1141278B1
EP1141278B1 EP99968130A EP99968130A EP1141278B1 EP 1141278 B1 EP1141278 B1 EP 1141278B1 EP 99968130 A EP99968130 A EP 99968130A EP 99968130 A EP99968130 A EP 99968130A EP 1141278 B1 EP1141278 B1 EP 1141278B1
Authority
EP
European Patent Office
Prior art keywords
seq
oligonucleotide
polymer
nucleic acid
pde4d
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP99968130A
Other languages
German (de)
English (en)
Other versions
EP1141278A2 (fr
Inventor
Roderic M. K. Dale
Amy Arrow
Terry Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oligos Etc Inc
Original Assignee
Oligos Etc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oligos Etc Inc filed Critical Oligos Etc Inc
Publication of EP1141278A2 publication Critical patent/EP1141278A2/fr
Application granted granted Critical
Publication of EP1141278B1 publication Critical patent/EP1141278B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Definitions

  • PDE 1 through PDE 9 There are multiple distinct phosphodiesterases (PDE 1 through PDE 9), most of which exist as two or more isozymes or splice variants that can differ in their cellular distribution, specificity toward hydrolysis of cAMP or cGMP, selective inhibition by various compounds, and sensitivity to regulation by calcium, calmodulin, cAMP, and cGMP ( J.A. Beavo in Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action.
  • Phosphodiesterase Isozymes Background, Nomenclature, and Implications. Eds. Beavo, J. and Houslay, M.D., John Wiley and Son, New York, 1990, pp. 3-15 and T.J. Torphy et al., "Novel Phosphodiesterases Inhibitors for the Therapy of Asthma", Drug News & Prospective, 6(4) May 1993, pp. 203-214 ).
  • the PDE4 family which is specific for cAMP, is composed of at least 4 isozymes (a-d), and multiple splice variants ( Houslay, M.D., et al. in Advances in Pharmacology 44, Eds. J. August et al., p.225, 1998 ). In total, there may be over 20 PDE4 isoforms expressed in a cell specific pattern regulated by a number of different promoters.
  • PDE4 is present in the brain and major inflammatory cells and has been found in abnormally elevated levels in a number of diseases including atopic dermatitis or eczema, asthma, and hay fever ( ASTI Connections, Vol. 8 #1 (1996) p. 3 and J. of Allergy and Clinical Immunology 70:452-457,1982 ).
  • Disease states for which selective PDE4 inhibitors have been sought include: asthma, atopic dermatitis, depression, reperfusion injury, septic shock, toxic shock, endotoxic shock, adult respiratory distress syndrome, autoimmune diabetes, diabetes insipidus, multi-infarct dementia, AIDS, cancer, Crohn's disease, multiple sclerosis, cerebral ischemia, psoriasis, allograft rejection, restenosis, ulcerative colitis, cachexia, cerebral malaria, allergic rhino-conjunctivitis, osteoarthritis, rheumatoid arthritis, chronic bronchitis, eosinophilic granuloma, and autoimmune encephalomyelitis (Houslay et al., 1998).
  • elevated PDE4 activity can be detected in their peripheral blood mononuclear leukocytes, T cells, mast cells, neutrophils and basophils. This increased PDE activity decreases cAMP levels and results in a breakdown of cAMP control in these cells, which in turn results in increased immune response in the blood and tissues of affected individuals.
  • PDE inhibitors influence multiple functional pathways, act on multiple immune and inflammatory pathways, and influence synthesis or release of numerous immune mediators ( J.M. Hanifin and S.C. Chan, "Atopic Dermatitis-Therapeutic Implication for New Phosphodiesterase Inhibitors, Monocyte Dysregulation of T Cells" in AACI News, 7/2, 1995 ; J.M. Hanifin et al., "Type 4 Phosphodiesterase Inhibitors Have Clinical and In Vitro Anti-inflammatory Effects in Atopic Dermatitis," J. of Invest. Derm., 1996, 107:51-56 and Cohen, V.L. in INC's 7th Annual Conference on Asthma and Allergy (Oct.
  • PDE4 inhibitors have shown them to be broad spectrum anti-inflammatory agents with impressive activity in models of asthma and other allergic disorders, including atopic dermatitis and hay fever.
  • PDE4 inhibitors that have been used clinically include theophylline, rolipram, denbufylline, CDP 840 (a tri-aryl ethane) and CP80633 (a pyrimidone).
  • PDE4 inhibitors have been shown to influence eosinophil responses, decrease basophil histamine release, decrease IgE, PGE2, and IL 10 synthesis, and decrease anti-CD3 stimulated IL4 production.
  • PDE4 inhibitors developed to date have been small molecule compounds which exhibit central nervous system and gastrointestinal effects. Although the first generation of PDE4 inhibitors have been effective in reducing PDE4 activity and alleviating a number of the inflammatory problems caused by overexpression of this enzyme, their effectiveness has been limited by mechanism related side effects and none of them can be used systemically because of nausea and vomiting ( ASTI Connections, Vol. 8 #1 (1996) p. 3 and Hanifin reference and Cohen, V.L. in INC's 7th Annual Conference on Asthma and Allergy (Oct. 27-28, 1997) - Phosphodiesterase 4 Inhibitors: Second Generation and Beyond ).
  • Oligonucleotide therapy i.e., the use of oligonucleotides to modulate the expression of specific genes, offers an opportunity to selectively modify the expression of genes without the undesirable non-specific toxic effects of more traditional therapeutics.
  • the use of antisense oligonucleotides has emerged as a powerful new approach for the treatment of many diseases. The preponderance of the work to date has focused on the use of antisense oligonucleotides as antiviral agents or as anticancer agents ( Wickstrom, E., Ed., Prospects for Antisense Nucleic Acid Therapy of Cancer.
  • the present invention provides end-blocked acid resistant nucleic acid polymers, e.g., end-blocked 2'-O-alkyl and 2'-O-alkyl-n(O-alkyl) oligonucleotides, for use in modulating PDE4D activity, either in vivo or in vitro.
  • end-blocked acid resistant nucleic acid polymers e.g., end-blocked 2'-O-alkyl and 2'-O-alkyl-n(O-alkyl) oligonucleotides
  • PDE4D polymers exhibit substantial stability at low pH, substantial resistance to nuclease degradation, and binding specificity both in vivo and in vitro.
  • the nucleotides of these polymers may be either ribonucleotides and/or deoxyribonucleotides, and may be targeted to DNA sequences involved in the expression of PDE4D (e.g., coding sequences, promoter sequences, enhancer sequences, etc.) or to PDE4D mRNA.
  • PDE4D e.g., coding sequences, promoter sequences, enhancer sequences, etc.
  • PDE4D mRNA e.g., coding sequences, promoter sequences, enhancer sequences, etc.
  • These low toxicity, highly specific, acid stable, end-blocked polymers represent an improved nucleic acid structure for therapeutic treatments of PDE4D-mediated diseases.
  • the 3', 5', or 3' and 5' acid stable, nuclease resistant ends confer improved bioavailability by increasing nuclease resistance.
  • the invention also provides pharmaceutical compositions comprised of polymers of the invention.
  • These pharmaceutical compositions may include any pharmaceutically acceptable carrier.
  • the pharmaceutical composition may also include additives such as adjuvants, stabilizers, fillers and the like.
  • the acid resistant polymers comprising a nucleic acid having a backbone structure modified from that of a naturally occurring nucleotide polymer ; and a blocking chemical modification at or near at least one end of the nucleic acid used for treating a patient in need of such treatment with a therapeutically effective amount of an polymers targeted to PDE4D.
  • the therapeutic effectiveness of an oligonucleotide targeted against PDE4D is demonstrated herein using data from preliminary human trials.
  • the invention also comprises methods of reducing the activity of one or more PDE4D enzyme comprising treating a patient with one or more antisense oligonucleotide polymers.
  • the oligonucleotide is targeted to mRNA coding for PDE4D.
  • the acid stable ends confer an improved stability on the modified nucleic acids in an acidic environment (e.g., the stomach, with a pH of 1 to 2), and thus increase bioavailability of the polymers in vivo.
  • an acidic environment e.g., the stomach, with a pH of 1 to 2
  • the end blocked nucleic acids are non-toxic to a subject treated with the modified nucleic acids.
  • the modified nucleic acids of the present invention e.g., 2'-O-alkyl and 2'-O-alkyl-n(O-alkyl) end-blocked oligonucleotides, do not display side effects commonly caused by therapeutic administration of regular polyanionic oligonucleotides, such as increased binding to serum and other proteins, stimulation of serum transaminases, decreases in platelet counts, and the like.
  • the acid stable ends confer an improved stability on the PDE4D oligonucleotides in the acid environments of lysosomal vesicles in macrophages and neutrophils.
  • PDE4D oligonucleotides of the present invention are readily encapsulated in charged liposomes.
  • the PDE4D polymers have low toxicity, i.e., mice parenterally treated with a PDE4D oligonucleotide of the invention exhibit an LD 50 of less than one at 400 mg/ml.
  • nucleic acid and “nucleic acid molecule” as used interchangeably herein, refer to a molecule comprised of nucleotides, i.e., ribonucleotides, deoxyribonucleotides, or both.
  • the term includes monomers and polymers of ribonucleotides and deoxyribonucleotides, with the ribonucleotide and/or deoxyribonucleotides being connected together, in the case of the polymers, via 5' to 3' linkages.
  • linkages may include any of the linkages known in the nucleic acid synthesis art including, for example, nucleic acids comprising 5' to 2' linkages.
  • the nucleotides used in the nucleic acid molecule may be naturally occurring or may be synthetically produced analogues that are capable of forming base-pair relationships with naturally occurring base pairs.
  • Examples of non-naturally occurring bases that are capable of forming base-pairing relationships include, but are not limited to, aza and deaza pyrimidine analogues, aza and deaza purine analogues, and other heterocyclic base analogues, wherein one or more of the carbon and nitrogen atoms of the purine and pyrimidine rings have been substituted by heteroatoms, e.g., oxygen, sulfur, selenium, phosphorus, and the like.
  • oligonucleotide refers to a nucleic acid molecule comprising nucleotides, in a number as given in the claimed sequences.
  • PDE4D oligonucleotide refers to an oligonucleotide that is targeted to sequences that affect PDE4D expression or activity. These include, but are not limited to, PDE4D DNA coding sequences, PDE4D DNA promoter sequences, PDE4D DNA enhancer sequences, mRNA encoding PDE4D and the like.
  • modified oligonucleotide and “modified nucleic acid molecule” as used herein refer to nucleic acids, including oligonucleotides, with one or more chemical modifications at the molecular level of the natural molecular structures of all or any of the nucleic acid bases, sugar moieties, internucleoside phosphate linkages, as well as molecules having added substituents, such as diamines, cholesteryl or other lipophilic groups, or a combination of modifications at these sites.
  • the internucleoside phosphate linkages can be phosphodiester, phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothioate and/or sulfone internucleotide linkages, or 3'-3', 2'-5' or 5'-5' linkages, and combinations of such similar linkages (to produce mixed backbone modified oligonucleotides).
  • the modifications can be internal (single or repeated) or at the end(s) of the oligonucleotide molecule and can include additions to the molecule of the internucleoside phosphate linkages, such as cholesteryl, diamine compounds with varying numbers of carbon residues between amino groups and terminal ribose, deoxyribose and phosphate modifications which cleave or crosslink to the opposite chains or to associated enzymes or other proteins.
  • Electrophilic groups such as ribose-dialdehyde could covalently link with an epsilon amino group of the lysyl-residue of such a protein.
  • modified oligonucleotides also includes oligonucleotides comprising modifications to the sugar moieties such as 2'-substituted ribonucleotides, or deoxyribonucleotide monomers, any of which are connected together via 5' to 3' linkages.
  • Modified oligonucleotides may also be comprised of PNA or morpholino modified backbones where target specificity of the sequence is maintained.
  • nucleic acid backbone refers to the structure of the chemical moiety linking nucleotides in a molecule. This may include structures formed from any and all means of chemically linking nucleotides.
  • a modified backbone as used herein includes modifications to the chemical linkage between nucleotides, as well as other modifications that may be used to enhance stability and affinity, such as modifications to the sugar structure. For example an a-anomer of deoxyribose may be used, where the base is inverted with respect to the natural b-anomer.
  • the 2'-OH of the sugar group may be altered to 2'-O-alkyl or 2'-O-alkyl-n(O-alkyl), which provides resistance to degradation without comprising affinity.
  • the term "acidification” and “protonation/acidification” as used interchangeably herein refers to the process by which protons (or positive hydrogen ions) are added to proton acceptor sites on a nucleic acid.
  • the proton acceptor sites include the amine groups on the base structures of the nucleic acid and the phosphate of the phosphodiester linkages. As the pH is decreased, the number of these acceptor sites which are protonated increases, resulting in a more highly protonated/acidified nucleic acid.
  • nucleic acid refers to a nucleic acid that, when dissolved in water at a concentration of approximately 16 A 260 per ml, has a pH lower than physiological pH, i.e., lower than approximately pH 7.
  • Modified nucleic acids, nuclease-resistant nucleic acids, and antisense nucleic acids are meant to be encompassed by this definition.
  • nucleic acids are protonated/acidified by adding protons to the reactive sites on a nucleic acid, although other modifications that will decrease the pH of the nucleic acid can also be used and are intended to be encompassed by this term.
  • end-blocked refers to a nucleic acid with a chemical modification at the molecular level that prevents the degradation of selected nucleotides, e.g., by nuclease action. This chemical modification is positioned such that it protects the integral portion of the nucleic acid, for example the coding region of an antisense oligonucleotide.
  • An end block may be a 3' end block or a 5' end block.
  • a 3' end block may be at the 3'-most position of the molecule, or it may be internal to the 3' ends, provided it is 3' of the integral sequences of the nucleic acid.
  • substantially nuclease resistant refers to nucleic acids that are resistant to nuclease degradation, as compared to naturally occurring or unmodified nucleic acids.
  • Modified nucleic acids of the invention are at least 1.25 times more resistant to nuclease degradation than their unmodified counterpart, more preferably at least 2 times more resistant, even more preferably at least 5 times more resistant, and most preferably at least 10 times more resistant than their unmodified counterpart.
  • Such substantially nuclease resistant nucleic acids include, but are not limited to, nucleic acids with modified backbones such as 2'-O-methyl, 2'-0-alkyl, 2'-O-alkyl-n(O-alkyl).
  • substantially acid resistant refers to nucleic acids that are resistant to acid degradation as compared to unmodified nucleic acids.
  • the relative acid resistance of a nucleic acid will be measured by comparing the percent degradation of a resistant nucleic acid with the percent degradation of its unmodified counterpart (i.e., a corresponding nucleic acid with "normal" backbone, bases, and phosphodiester linkages).
  • a nucleic acid that is acid resistant is preferably at least 1.5 times more resistant to acid degradation, at least 2 times more resistant, even more preferably at least 5 times more resistant, and most preferably at least 10 times more resistant than their unmodified counterpart.
  • polymer refers to a nucleic acid or oligonucleotide molecule having both 1) a modified nucleic acid backbone and 2) at least one end-block at or near the end of the molecule.
  • LD 50 is the dose of an active substance that will result in 50 per cent lethality in all treated experimental animals. Although this usually refers to invasive administration, such as oral, parenteral, and the like, it may also apply to toxicity using less invasive methods of administration, such as topical applications of the active substance.
  • alkyl refers to a branched or unbranched saturated hydrocarbon chain containing 1-6 carbon atoms, such as methyl, ethyl, propyl, tert-butyl, n-hexyl and the like.
  • sensitivity refers to the relative strength of recognition of a nucleic acid by a binding partner, e.g., an oligonucleotide complementary to the nucleic acids of interest, i.e., PDE4D.
  • the recognition of the binding partner to the sequence of interest must be significantly greater than the recognition of background sequences, and preferably the strength of recognition of the binding partner is at least 10 times, more preferably at least 100 times greater, and even more preferably at least 500 times greater than recognition of background proteins.
  • a selective binding partner refers to the preferential binding of a binding partner to a particular nucleic acid sequence.
  • a selective binding partner is at least 10 times, more preferably 100 times, and even more preferably 1000 times more likely to bind to its designated polynucleotide sequence than to any other background sequence.
  • treatment means obtaining a desired pharmacologic and/or physiologic effect.
  • the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease.
  • Treatment covers any treatment of a disease in a mammal, particularly a human, and includes:
  • terapéuticaally effective amount is meant a nontoxic but sufficient amount of a compound to provide the desired therapeutic effect, in the present case, that dose of modified nucleic acid which will be effective in relieving, ameliorating, or preventing symptoms of the condition or disease being treated.
  • Antisense therapeutic compounds are oligonucleotides, preferably nuclease resistant, complementary to the mRNA coding for a particular protein. Antisense oligonucleotides generally interfere with the transcription or translation of the targeted gene and thereby reduce expression of the target gene. Because of the great specificity that is possible with antisense there are far fewer, if any, side affects.
  • the invention also describes either neutral or protonated/acidified oligonucleotide polymers that are substantially nuclease resistant.
  • This example includes oligonucleotide polymers completely or partially derivatized by phosphorothioate linkages, 2'-deoxy-erythropentofuranosyl, 2'-fluoro, 2'-O-alkyl or 2'-O-alkyl-n(O-alkyl) phosphodiesters, p-ethoxy oligonucleotides, p-isopropyl oligonucleotides, phosporamidates, chimeric linkages, and any other backbone modifications.
  • This example also includes other modifications that render the oligonucleotide polymers substantially resistant to endogenous nuclease activity.
  • Additional methods of rendering an oligonucleotide polymer nuclease resistant include, but are not limited to, covalently modifying the purine or pyrimidine bases that comprise the oligonucleotide polymer.
  • bases may be methylated, hydroxymethylated, or otherwise substituted (e.g., glycosylated) such that the oligonucleotide polymers comprising the modified bases are rendered substantially nuclease resistant.
  • the 3' and/or 5' ends of the nucleic acid sequence are preferably attached to an exonuclease blocking function.
  • one or more phosphorothioate nucleotides can be placed at either end of the oligoribonucleotide.
  • one or more inverted bases can be placed on either end of the oligonucleotide polymer, or one or more alkyl moieties, e.g., butanol-substituted nucleotides or chemical groups can be placed on one or more ends of the oligonucleotide polymer.
  • 5' and 3' end blocking groups may include one or more phosphorothioate nucleotides (but typically fewer than six), inverted base linkages, or alkyl, alkenyl, or alkynl groups or substituted nucleotides or 2'-O-alkyl-n(O-alkyl).
  • a partial list of blocking groups includes inverted bases, dideoxynucleotides, methylphosphates, alkyl groups, alcohol groups, aryl groups, cordycepin, cytosine arabanoside, 2'-methoxyethoxy nucleotides, phosphoramidates, a peptide linkage, dinitrophenyl group, 2'- or 3'-O-methyl bases with phosphorothioate linkages, 3'-O-methyl bases, fluorescein, cholesterol, biotin, acridine, rhodamine, psoralen, glyceryl, methyl phosphonates, a hexa-ethyloxy-glycol, butanol, hexanol, and 3'-O-alkyls.
  • An enzyme-resistant butanol preferably has the structure OH-CH 2 CH 2 CH 2 CH 2 (4-hydroxybutyl) which is also referred to as a C4 spacer.
  • the relative nuclease resistance of a nucleic acid can be measured by comparing the percent digestion of a resistant nucleic acid with the percent digestion of its unmodified counterpart (i.e., a corresponding nucleic acid with "normal" backbone, bases, and phosphodiester linkage). Percent degradation may be determined by using analytical HPLC to assess the loss of full length nucleic acids, or by any other suitable methods (e.g., by visualizing the products on a sequencing gel using staining, autoradiography, fluorescence, etc., or measuring a shift in optical density). Degradation is generally measured as a function of time.
  • Comparison between unmodified and modified nucleic acids can be made by ratioing the percentage of intact modified nucleic acid to the percentage of intact unmodified nucleic acid. For example, if, after 15 minutes of exposure to a nuclease, 25% (i.e., 75% degraded) of an unmodified nucleic acid is intact, and 50% (i.e., 50% degraded) of a modified nucleic acid is intact, the modified nucleic acid is said to be 2 times (50% divided by 25%) more resistant to nuclease degradation than is the unmodified nucleic acid.
  • a substantially nuclease resistant nucleic acid will be at least about 1.25 times more resistant to nuclease degradation than an unmodified nucleic acid with a corresponding sequence, typically at least about 1.5 times more resistant, preferably about 2 times more resistant, more preferably at least about 5 times more resistant, and even more preferably at least about 10 times more resistant after 15 minutes of nuclease exposure.
  • Percent acid degradation may be determined by using analytical HPLC to assess the loss of full length nucleic acids, or by any other suitable methods (e.g., by visualizing the products on a sequencing gel using staining, autoradiography, fluorescence, etc., or measuring a shift in optical density). Degradation is generally measured as a function of time.
  • Comparison between unmodified and modified nucleic acids can be made by ratioing the percentage of intact modified nucleic acid to the percentage of intact unmodified nucleic acid. For example, if, after 30 minutes of exposure to a low pH environment, 25% (i.e., 75% degraded) of an unmodified nucleic acid is intact, and 50% (i.e., 50% degraded) of a modified nucleic acid is intact, the modified nucleic acid is said to be 2 times (50% divided by 25%) more resistant to nuclease degradation than is the unmodified nucleic acid.
  • substantially "acid resistant" nucleic acids will be at least about 1.25 times more resistant to acid degradation than an unmodified nucleic acid with a corresponding sequence, typically at least about 1.5 times more resistant, preferably about 1.75 more resistant, more preferably at least 5 times more resistant and even more preferably at least about 10 times more resistant after 30 minutes of exposure at 37°C to a pH of about 1.5 to about 4.5.
  • Acidification of nucleic acids is the process by which protons (or hydrogen atoms) are added to the reactive sites on a nucleic acid. As the pH is decreased, the number of reactive sites protonated increases and the result is a more highly protonated/acidified nucleic acid. As the pH of the nucleic acid decreases, its bacterial inhibiting activity increases. Accordingly, the nucleic acids of the invention are protonated/acidified to give a pH when dissolved in water of less than pH 7 to about pH 1, or in preferred embodiments, pH 6 to about 1 or pH 5 to about 1.
  • the dissolved nucleic acids have a pH from pH 4.5 to about 1 or, in a preferred embodiment, a pH of 4.0 to about 1, or, in a more preferred embodiment, a pH of 3.0 to about 1, or, in another preferred embodiment, a pH of 2.0 to about 1.
  • the acid resistant polymer is used for treating a patient requiring such treatment comprising administering one or more oligonucleotide polymer(s) targeted to hybridize with one or more of the appropriate PDE4 mRNA(s) in a therapeutically effective amount.
  • the acid resistant polymer is used for treating a patient requiring such treatment comprising administering one or more oligonucleotide polymer(s) targeted to hybridize with one or more of the PDE4D mRNA(s) in an amount effective to reduce expression of one or more of the PDE4D enzymes.
  • the antisense oligonucleotide polymers are in a pharmaceutically acceptable carrier.
  • the targeted PDE4D gene sequence or sequences are selected from the group consisting of the PDE4D genes, their isozymes and their splice variants.
  • the acid resistant polymers and compositions of the invention are useful as analytical tools in the study of individual PDE4D isoforms and in therapeutic treatment.
  • the acid resistant polymers and compositions of the invention are useful for treating various diseases or disorders, including but not limited to: asthma, hay fever, atopic dermatitis, depression, reperfusion injury, septic shock, toxic shock, endotoxic shock, adult respiratory distress syndrome, autoimmune diabetes, diabetes insipidus, multi-infarct dementia, AIDS, cancer, Crohn's disease, multiple sclerosis, cerebral ischemia, psoriasis, allograft rejection, restenosis, ulcerative colitis, cachexia, cerebral malaria, allergic rhino-conjunctivitis, osteoarthritis, rheumatoid arthritis, chronic bronchitis, eosinophilic granuloma, and autoimmune encephalomyelitis.
  • Particular embodiments of the present invention are directed towards the treatment of the above diseases.
  • the presently described oligonucleotide polymers may be formulated with a variety of physiological carrier molecules.
  • the presently described oligonucleotide polymers may also be complexed with molecules that enhance their ability to enter the target cells. Examples of such molecules include, but are not limited to, carbohydrates, polyamines, amino acids, peptides, lipids, and molecules vital to cell growth.
  • the oligonucleotide polymers may be combined with a lipid, the resulting oligonucleotide polymer/lipid emulsion, or liposomal suspension may, inter alia, effectively increase the in vivo half-life of the oligonucleotide polymer.
  • cationic, anionic, and/or neutral lipid compositions or liposomes is generally described in International Publications Nos. WO 90/14074 , WO 91/16024 , WO 91/17424 , Pat. No. 4,897,355 , herein incorporated by reference.
  • oligonucleotide polymers directed at PDE4D targets may also be protonated/acidified to function in a dual role as phosphodiesterase inhibitors and antibacterial agents.
  • another embodiment of the presently described invention is the use of a PDE4D modulating therapeutic oligonucleotide polymer that is additionally protonated/acidified to increase cellular uptake, improve encapsulation in liposomes, so it can also serve as an antibiotic.
  • the oligonucleotide polymer may be complexed with a variety of well established compounds or structures that, for instance, further enhance the in vivo stability of the oligonucleotide polymer, or otherwise enhance its pharmacological properties (e.g., increase in vivo half-life, reduce toxicity, etc.).
  • Antisense oligonucleotide polymers may be targeted to particular functional domains of a gene or mRNA transcript.
  • the potential targets include, but are not limited to, regulatory regions, the 5'-untranslated region, the translational start site, the translational termination site, the 3'-untranslated region, exon/intron boundaries and splice sites, as well as sequences internal to the coding region.
  • the target gene, pre-mRNA, or mRNA sequence is examined for the presence of homopolymer runs (4 or more bases in a row) within the target sequence, the targeting of which should generally be avoided.
  • a region of the pre-mRNA, mRNA or DNA sequence within that domain is analyzed.
  • An analysis of the segment of the sequence extending approximately 5 to 100 bases or more upstream and downstream from a possible antisense target site is performed.
  • the locations of potentially stable secondary structures are defined as stem-loop structures with predicted melting temperatures above 20°C. This analysis can be performed using commercially available software such as OLIGO 4.0 for Mac, or OligoTech. Sequences involved in stem hybridization for loop-stem secondary structure formation are regarded as part of the secondary structure and are treated as a structural unit for the purposes of analysis and selection of an antisense oligonucleotide polymer.
  • antisense oligonucleotide polymers can be targeted to sequences of the gene, pre-mRNA, or mRNA with predicted secondary structure melting temperatures of less than 100°C (according to the commercially available analysis programs).
  • the secondary structure melting temperatures would be less than 60°C.
  • the secondary structure melting temperature would be less than 40°C.
  • secondary structure melting temperatures would be less than 20°C.
  • Oligonucleotide polymer sequences with stable loop structures or which form stable dimers should be avoided.
  • antisense oligonucleotide polymers with predicted secondary structure melting temperatures of less than 100°C are chosen.
  • the secondary structure melting temperatures would be less than 80°C.
  • the secondary structure melting temperatures would be less than 60°C.
  • the secondary structure melting temperatures would be less than 40°C.
  • the secondary structure melting temperature is less than 20°C.
  • homodimers by the antisense oligonucleotide polymers may compete with their ability to bind to target DNA or RNA.
  • Homopolymer runs of a single base ideally will be three bases or less within the oligonucleotide polymer sequence. Generally, within a target, those sequences with the lowest secondary structure melting temperatures (loop Tm), or no secondary structure work best.
  • Sequences of antisense oligonucleotide polymers useful as compositions and in methods of the present invention include the following: Target Gene: PDE4A (PDE4A) - - Acc# U68532 (SEQ ID NO:46), which is not part of the present invention Target Domain (Nucleotide Position #s) Antisense Oligonucleotide Sequence 59-35 tta gag cag gtc tcg cag aag aaa t, (SEQ ID NO: 1) 569-545 agc gtc agc atg tat gtc acc atc g, (SEQ ID NO: 2) 886-862 gct tgc tga ggt tct gga aga tgt c, (SEQ ID NO: 3) 1541-1518 aga gct tcc tcg act cct gac aat, (SEQ ID NO: 4)
  • an appropriate dosage of an antisense PDE4D oligonucleotide polymer, or mixture thereof may be determined by any of several well established methodologies. For instance, animal studies are commonly used to determine the maximal tolerable dose, or MTD, of bio-active agent per kilogram weight. In general, at least one of the animal species tested is mammalian. Those skilled in the art regularly extrapolate doses for efficacy and avoiding toxicity to other species, including human. Additionally, therapeutic dosages may also be altered depending upon factors such as the severity of infection and the size or species of the host.
  • Oligonucleotide polymers are preferably administered in a pharmaceutically acceptable carrier, via oral, intranasal, rectal, topical, intraperitoneal, intramuscular, subcutaneous, intracranial, subdermal, transdermal, intratracheal methods, or the like.
  • topical diseases are preferably treated or prevented by formulations designed for topical application.
  • preparations of oligonucleotide polymers may be provided by oral dosing.
  • pulmonary sites of disease e.g., asthma, may be treated both parenterally and by direct application of suitably formulated forms of the oligonucleotide polymers to the lung by inhalation therapy.
  • the oligonucleotide polymers can accumulate to relatively high levels in the kidneys, liver, spleen, lymph glands, adrenal gland, aorta, pancreas, bone marrow, heart, and salivary glands. Oligonucleotide polymers also tend to accumulate to a lesser extent in skeletal muscle, bladder, stomach, esophagus, duodenum, fat, and trachea. Still lower concentrations are typically found in the cerebral cortex, brain stem, cerebellum, spinal cord, cartilage, skin, thyroid, and prostate (see generally Crooke, 1993, Antisenve Research and Applications, CRC Press, Boca Raton, FL ).
  • treatment shall refer to any and all uses of the claimed oligonucleotide polymers that remedy a disease state or symptoms, or otherwise prevent, hinder, retard, or reverse the progression of disease or other undesirable symptoms in any way whatsoever.
  • animal hosts that may be treated using the oligonucleotide polymers of the present invention include, but are not limited to, invertebrates, vertebrates, birds, mammals such as pigs, goats, sheep, cows, dogs, cats, and particularly humans. Oligonucleotide polymers are designed to be appropriate to the particular animal to be treated.
  • nucleic acids can be protonated/acidified with acid, including but not limited to, phosphoric acid, nitric acid, hydrochloric acid, acetic acid, etc.
  • acid may be combined with nucleic acids in solution, or alternatively, the nucleic acids may be dissolved in an acidic solution. Excess acid may be removed by chromatography or in some cases by drying the nucleic acid.
  • nucleic acids of the present invention may be separated from any undesired components such as excess acid.
  • the skilled artisan would know of many ways to separate the oligonucleotide polymers from undesired components.
  • the oligonucleotide polymer solution may be subjected to chromatography following protonation.
  • the oligonucleotide polymer solution is run over a poly(styrene-divinylbenzene) based resin column (e.g., Hamilton's PRP or Polymer Labs' PLRP) following protonation.
  • a poly(styrene-divinylbenzene) based resin column e.g., Hamilton's PRP or Polymer Labs' PLRP
  • the protonated/acidified nucleic acids can be used directly, or in a preferred embodiment, processed further to remove any excess acid and salt via precipitation, reverse phase chromatography, diafiltration, or gel filtration.
  • the protonated/acidified oligos can be concentrated by precipitation, lyophilization, solvent evaporation, etc.
  • the acidified nucleic acid preparations of the invention When suspended in water or saline, the acidified nucleic acid preparations of the invention typically exhibit a pH between 0.5 and 4.5 depending upon 1) the level of protonation/acidification, which can be determined by how much acid is used in the acidification process, and 2) the concentration of the nucleic acid.
  • nucleic acids can be protonated by passage over a cation exchange column charged with hydrogen ions.
  • protonated oligonucleotide polymers in a sequence independent manner, exhibit antibacterial properties.
  • the protonated oligonucleotide polymers of the invention are protonated/acidified to give a pH when dissolved in water of less than pH 7 to about pH 1, or in preferred embodiments, pH 6 to about 1 or pH 5 to about 1.
  • the dissolved nucleic acids have a pH from pH 4.5 to about 1 or, in a preferred embodiment, a pH of 4.0 to about 1, or, in a more preferred embodiment, a pH of 3.0 to about 1, or, in another preferred embodiment, a pH of 2.0 to about 1.
  • Oligonucleotide polymers may be formulated with a variety of physiological carrier molecules for in vivo use.
  • the oligonucleotide polymers may be combined with a lipid, cationic lipid, or anionic lipid (which may be preferred for protonated/acidified oligonucleotide polymers) and the resulting oligonucleotide polymer/lipid emulsion, or liposomal suspension may, inter alia, effectively increase the in vivo half-life of the oligonucleotide polymer.
  • an appropriate dosage of a PDE4 modulating oligonucleotide polymer, or mixture thereof may be determined by any of several well established methodologies. For instance, animal studies are commonly used to determine the maximal tolerable dose, or MTD, of bio-active agent per kilogram weight. In general, at least one of the animal species tested is mammalian. Those skilled in the art regularly extrapolate doses for efficacy and avoiding toxicity to other species, including human. Additionally, therapeutic dosages may also be altered depending upon factors such as the severity of the disease, and the size or species of the host.
  • anionic liposomes are thought to have a number of advantages over cationic liposomes ( R.J. Lee and L. Huang, “Lipidic Vector Systems for Gene Transfer", in Critical Reviews in Therapeutic Drug Carrier Systems 14(2):173-206 (1997) ).
  • anionic liposomes are likely to be less toxic than cationic liposomes, they exhibit lower non-specific uptake, and they can be targeted with the appropriate ligands to specific cells.
  • the use of cationic, anionic, and/or neutral lipid compositions or liposomes is generally described in International Publications Nos. WO 90/14074 , WO 91/16024 , WO 91/17424 , and U.S. Pat. No. 4,897,355 ,
  • the oligonucleotide polymers may be targeted to specific cell types by the incorporation of suitable targeting agents (i.e., specific antibodies or receptors) into the oligonucleotide polymer/lipid complex.
  • suitable targeting agents i.e., specific antibodies or receptors
  • compositions containing oligonucleotide polymers of the invention in intimate admixture with a pharmaceutical carrier can be prepared according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral, topical, aerosol (for topical or inhalation therapy), suppository, parenteral, or spinal injection.
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations (such as, for example, suspension, elixirs, and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets). Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques.
  • preparations may comprise an aqueous solution of a water soluble, or solubilized, and pharmaceutically acceptable form of the oligonucleotide polymer in an appropriate saline solution.
  • injectable suspensions may also be prepared using appropriate liquid carriers, suspending agents, agents for adjusting the isotonicity, preserving agents, and the like.
  • Actual methods for preparing parenterally administrable compositions and adjustments necessary for administration to subjects will be shown or apparent to those skilled in the art and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th Ed., Mack Publishing Company, Easton, PA (1980 ), which is incorporated herein by reference.
  • the presently described oligonucleotide polymers should be parenterally administered at concentrations below the maximal tolerable dose (MTD) established for the oligonucleotides.
  • MTD maximal tolerable dose
  • the carrier may take a wide variety of forms depending on the preparation, which may be a cream, dressing, gel, lotion, ointment, or liquid.
  • Aerosols are prepared by dissolving or suspending the oligonucleotide in a propellant such as ethyl alcohol or in propellant and solvent phases.
  • a propellant such as ethyl alcohol or in propellant and solvent phases.
  • the pharmaceutical compositions for topical or aerosol form will generally contain from about 0.01% by weight (of the oligonucleotide) to about 40% by weight, preferably about (0.02% to about 10% by weight, and more preferably about 0.05% to about 5% by weight depending on the particular form employed.
  • Suppositories are prepared by mixing the oligonucleotide polymer with a lipid vehicle such as theobroma oil, cacao butter, glycerin, gelatin, or polyoxyethylene glycols.
  • a lipid vehicle such as theobroma oil, cacao butter, glycerin, gelatin, or polyoxyethylene glycols.
  • oligonucleotide polymers may be administered to the body by virtually any means used to administer conventional therapeutics.
  • a variety of delivery systems are well known in the art for delivering bioactive compounds to an animal. These systems include, but are not limited to, intravenous or intra-muscular or intra-tracheal injection, nasal spray, aerosols for inhalation, and oral or suppository administration.
  • the specific delivery system used depends on the location of the disease, and it is well within the skill of one in the art to determine the location of the disease and to select an appropriate delivery system.
  • OE-2a is a 2' O-methyl RNA phosphodiester linked, with 5' and 3' ends blocked with inverted Ts, and is targeted against the human PDE4 gene.
  • OE-2a was dissolved at 35 mg/ml (7.7 ⁇ Molar) in water at approximately pH 3 and used to treat a 37 year old male with a history of severe recurrent atopic dermatitis. The dermatitis was specifically eradicated with OE-2a. In addition, future occurrences of atopic dermatitis have been completely eliminated.
  • Atopic dermatitis is a chronic disorder characterized by intensely pruritic inflamed papules. The inflammatory response is associated with over-production of IgE by B lymphocytes. Higher levels of PDE4 have been reported for individuals with atopic dermatitis.
  • An antisense oligonucleotide polymer, OE-2a, specifically targeted to PDE4 was applied to a 2" by 3" segment of the left forearm.
  • a second oligo, OE-1 was applied to another segment of the same arm.
  • OE-1 has a similar base distribution to OE-2a, but is homologous to a bacterial gene. Oligonucleotide polymers were applied twice at 12 hour intervals.
  • OE-2a was successful at clearing the dermatitis on the area to which it was applied. OE-1 had no effect. The patient commented prior to the second treatment that the itching had stopped on the area corresponding to the OE-2a after about 6 hours.
  • Treatment on the second arm was initiated at this time exclusively with OE-2a. Again there were 2 treatments 12 hours apart. The patient remarked that all itching had ceased within 6 hours. The dermatitis was completely cleared within 12 hours of the second treatment.
  • OE-2a at 35 mg/ml (7.7 ⁇ Molar) in water at approximately pH 3 was used to treat a case of T cell mediated contact dermatitis triggered by poison ivy.
  • the dermatitis was completely eliminated with 2 treatments, and secondary eruptions on other areas of the infected individual were prevented.
  • OE-2a at 43.6 mg/ml (7.7 ⁇ Molar) and approximately pH 7 was able to prevent both an immediate and delayed-type hypersensitivity response when applied within minutes of receiving multiple wasp stings.
  • the patient was in severe pain and hysterical.
  • OE-2a was administered immediately. Within 5 minutes the patient was calm and pain free. Remarkably, administration of the OE-2a within 5 minutes of receiving the stings completely prevented any immediate wheal and flare reaction, as well as any delayed reaction.
  • OE-2a was successfully used to treat a case of chemically induced contact dermatitis that had failed to respond to standard dermatological treatments.
  • OE-2a OE-2a oligonucleotide polymer
  • the males ranged in age from 45 years old to 73 years old.
  • the weights ranged from 175 pounds to 230 pounds.
  • a sterile nasal spray container was filled with a solution containing OE-2a dissolved in normal saline.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)

Claims (8)

  1. Polymère résistant aux acides complémentaire de PDE4D pour moduler l'activité PDE4D comprenant :
    - un acide nucléique ayant une structure squelettique modifiée par rapport à celle d'un polymère nucléotidique naturel ; et
    - une modification chimique bloquante au niveau ou proche d'au moins une extrémité de l'acide nucléique ;
    dans lequel le polymère est caractérisé par une stabilité au pH d'au moins 30 minutes à un pH d'environ 1,5 à 4,5 et une résistance aux nucléases d'au moins deux fois celle d'un acide nucléique naturel ayant le même nombre de nucléotides, dans lequel l'acide nucléique a une séquence choisie dans le groupe consistant en: SEQ ID NO: 31 ; SEQ ID NO: 32 ; SEQ ID NO: 33 ; SEQ ID NO: 34 ; SEQ ID NO: 35 ; SEQ ID NO: 36 ; SEQ ID NO: 37 ; SEQ ID NO: 38 ; SEQ ID NO: 39 ; SEQ ID NO: 40 ; SEQ ID NO: 41 ; SEQ ID NO: 42 ; SEQ ID NO: 43 ; SEQ ID NO: 44 ; et SEQ ID NO: 45.
  2. Polymère selon la revendication 1, dans lequel la structure squelettique comprend un ou plusieurs groupements du groupe consistant en : 2'-O-méthyle, 2'-O-alkyle et 2'-O-alkyl-n(O-alkyl).
  3. Polymère selon les revendications 1 ou 2, dans lequel le polymère s'hybride aux séquences d'ADN de PDE4D.
  4. Polymère selon les revendications 1 ou 2, dans lequel le polymère s'hybride à un ARNm de PDE4D.
  5. Polymère selon l'une des revendications 1, 2, 3 ou 4, dans lequel le polymère est protoné pour avoir un pH inférieur à 7.
  6. Composition pharmaceutique composée d'un polymère selon l'une quelconque des revendications 1 à 5, et d'un vecteur pharmaceutiquement acceptable.
  7. Composition pharmaceutique selon la revendication 6, dans laquelle ledit polymère est protoné pour avoir un pH inférieur à 7.
  8. Utilisation comme médicament d'un ou plusieurs des polymères résistants aux acides selon l'une quelconque des revendications 1 à 5.
EP99968130A 1998-12-30 1999-12-15 Inhibiteurs de la phosphodiesterase pde4d utilises a des fins therapeutiques Expired - Lifetime EP1141278B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US364626 1994-12-27
US22358698A 1998-12-30 1998-12-30
US36462699A 1999-07-29 1999-07-29
PCT/US1999/029976 WO2000040714A2 (fr) 1998-12-30 1999-12-15 Inhibiteurs de la phosphodiesterase utilises a des fins therapeutiques
US223586 2002-08-16

Publications (2)

Publication Number Publication Date
EP1141278A2 EP1141278A2 (fr) 2001-10-10
EP1141278B1 true EP1141278B1 (fr) 2008-02-27

Family

ID=26917934

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99968130A Expired - Lifetime EP1141278B1 (fr) 1998-12-30 1999-12-15 Inhibiteurs de la phosphodiesterase pde4d utilises a des fins therapeutiques

Country Status (8)

Country Link
US (1) US20030045490A1 (fr)
EP (1) EP1141278B1 (fr)
JP (1) JP4787409B2 (fr)
AT (1) ATE387498T1 (fr)
AU (1) AU781577B2 (fr)
CA (1) CA2357950C (fr)
DE (1) DE69938256D1 (fr)
WO (1) WO2000040714A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030054531A1 (en) * 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
JP4999255B2 (ja) * 2001-07-10 2012-08-15 レイクウッド−アメディックス，インコーポレーテッド オリゴヌクレオチド含有薬理学的組成物およびその使用
US20030082590A1 (en) * 2001-07-15 2003-05-01 Keck Graduate Institute Exponential nucleic acid amplification using nicking endonucleases
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
JP2006500068A (ja) * 2002-09-25 2006-01-05 デコード ジェネティクス イーエッチエフ． ヒト脳卒中の罹患性遺伝子；治療法
AU2003301894A1 (en) * 2002-11-08 2004-06-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
AU2003274082A1 (en) * 2002-11-08 2004-06-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4a (pde4a)
CA2539752A1 (fr) 2003-09-29 2005-04-07 Topigen Pharmaceutique Inc. Compositions oligonucleotidiques et procedes de traitement de maladies associees a un etat inflammatoire
AU2006278229B2 (en) * 2005-08-09 2011-10-27 Ares Trading S.A. Methods for treating B-cell malignancies using TACI-Ig fusion molecule
JP5118037B2 (ja) * 2005-08-09 2013-01-16 ザイモジェネティクス， インコーポレイテッド Ｔａｃｉ融合分子を用いた異常細胞増殖の処置及び予防のための方法
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
US8673873B1 (en) * 2005-12-28 2014-03-18 Alcon Research, Ltd. RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
AU2007249223B2 (en) 2006-05-15 2012-08-02 Ares Trading S.A. Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
CN101448847A (zh) 2006-05-19 2009-06-03 托皮根药品公司 影响磷酸二酯酶表达的寡核苷酸
EP2152877A2 (fr) * 2007-05-02 2010-02-17 Sirna Therapeutics Inc. INHIBITION MÉDIÉE PAR INTERFÉRENCE ARN DE L'EXPRESSION GÉNIQUE DE LA PHOSPHODIESTÉRASE DE TYPE 4 DE NUCLÉOTIDES CYCLIQUES (PDE4B), AU MOYEN D'ACIDE NUCLÉIQUE INTERFÉRANT COURT (siNA)
EP2152878A2 (fr) * 2007-05-02 2010-02-17 Sirna Therapeutics Inc. INHIBITION MÉDIÉE PAR INTERFÉRENCE ARN DE L'EXPRESSION GÉNIQUE DE LA PHOSPHODIESTÉRASE DE TYPE 4 DE NUCLÉOTIDES CYCLIQUES (PDE4B), AU MOYEN D'ACIDE NUCLÉIQUE INTERFÉRANT COURT (siNA)
EP2152870A2 (fr) * 2007-05-02 2010-02-17 Sirna Therapeutics Inc. INHIBITION MÉDIÉE PAR INTERFÉRENCE ARN DE L'EXPRESSION GÉNIQUE DE LA PHOSPHODIESTÉRASE DE TYPE 4 DE NUCLÉOTIDES CYCLIQUES (PDE4B), AU MOYEN D'ACIDE NUCLÉIQUE INTERFÉRANT COURT (siNA)
WO2008137751A2 (fr) * 2007-05-02 2008-11-13 Sirna Therapeutics, Inc. INHIBITION MÉDIÉE PAR INTERFÉRENCE ARN DE L'EXPRESSION GÉNIQUE DE LA PHOSPHODIESTÉRASE DE TYPE 4 DE NUCLÉOTIDES CYCLIQUES (PDE4B), AU MOYEN D'ACIDE NUCLÉIQUE INTERFÉRANT COURT (siNA)
US8244352B2 (en) * 2008-06-19 2012-08-14 Cardiac Pacemakers, Inc. Pacing catheter releasing conductive liquid
WO2020102374A1 (fr) * 2018-11-14 2020-05-22 The Board Of Trustees Of The Leland Stanford Junior University Ciblage de complexes makap-pde4d3 dans une maladie neurodégénérative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1443051A3 (fr) * 1990-08-13 2005-08-17 Isis Pharmaceuticals, Inc. oligonucléotides modifiés par du sucre, détectant et modulant l'expression de gènes
IL108206A0 (en) * 1993-01-06 1994-04-12 Univ Johns Hopkins Oligomers having improved stability at acid ph
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
WO1996020281A1 (fr) * 1994-12-23 1996-07-04 Celltech Therapeutics Limited Ivc du type phosphodiesterase humaine, sa preparation et son utilisation
EP0771794B1 (fr) * 1995-05-19 2006-05-03 Kyowa Hakko Kogyo Co., Ltd. Composes heterocycliques contenant de l'oxygene
US5849902A (en) * 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
AU2197600A (en) * 1998-12-30 2000-07-24 Oligos Etc. Inc. Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof

Also Published As

Publication number Publication date
CA2357950C (fr) 2013-07-23
AU2480800A (en) 2000-07-24
JP4787409B2 (ja) 2011-10-05
DE69938256D1 (fr) 2008-04-10
EP1141278A2 (fr) 2001-10-10
WO2000040714A3 (fr) 2000-11-02
CA2357950A1 (fr) 2000-07-13
WO2000040714A2 (fr) 2000-07-13
JP2002534086A (ja) 2002-10-15
AU781577B2 (en) 2005-06-02
ATE387498T1 (de) 2008-03-15
US20030045490A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
EP1141278B1 (fr) Inhibiteurs de la phosphodiesterase pde4d utilises a des fins therapeutiques
US10538768B2 (en) Modified TGF-beta oligonucleotides
US20220170025A1 (en) Compositions and methods for inhibiting gene expression in the central nervous system
JP4977035B2 (ja) 腫瘍の治療における、ＴＧＦ−β、ＶＥＧＦ、インターロイキン−１０、Ｃ−ＪＵＮ、Ｃ−ＦＯＳまたはプロスタグランジンＥ２遺伝子にアンチセンスなオリゴヌクレオチドの低適用量の使用
US5681747A (en) Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
JPH11511014A (ja) 免疫刺激応答が低減した遺伝子発現の調節法
IL194419A (en) Dsrna to inhibit the expression of a 5eg gene in a human cell, a pharmaceutical compound containing it, a vector method
JP2022082544A (ja) 酸性アルファ－グルコシダーゼ遺伝子に関連する疾患を処置するためのアンチセンスオリゴマーおよびそれを用いる方法
JP2003505080A (ja) ヒトｅｇ５の発現を阻害するためのオリゴヌクレオチド
US6537973B1 (en) Oligonucleotide inhibition of protein kinase C
US6417169B1 (en) Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
WO2022077024A1 (fr) Administration sélective d'oligonucléotides à des cellules gliales
US20110086901A9 (en) Oligonucleotides affecting expression of phosphodiesterases
US20030060438A1 (en) Oligonucleotides and other modulators of the NK-1 receptor pathway and therapeutic uses thereof
WO2021157730A1 (fr) Médicament à base d'acide nucléique et utilisation associée
JP4690649B2 (ja) 標的化された遺伝子発現阻害のための新規なオリゴリボヌクレオチド誘導体
US5922686A (en) Oligonucleotide modulation of protein kinase C
TW202146652A (zh) Ｓｃｎ１ａ基因之表現及／或功能調節劑
JPWO2021119226A5 (fr)
WO1998049287A2 (fr) Oligonucleotides antisens specifiques d'une thymidylate synthase
CN117904110A (zh) 用于抑制DPP4的siRNA及其修饰物与应用
WO2023192828A2 (fr) Compositions et méthodes de traitement des maladies liées à l'angiopoïétine 7 (angptl7)
TW202405174A (zh) 用於抑制超氧化物歧化酶1(SOD1)表現之RNAi藥劑、其組合物及使用方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010730

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20041203

R17C First examination report despatched (corrected)

Effective date: 20041203

RTI1 Title (correction)

Free format text: THERAPEUTIC PDE4D PHOSPHODIESTERASE INHIBITORS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

XX Miscellaneous (additional remarks)

Free format text: DERZEIT SIND DIE WIPO-PUBLIKATIONSDATEN A3 NICHT VERFUEGBAR.

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69938256

Country of ref document: DE

Date of ref document: 20080410

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080227

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080607

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080527

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080721

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080227

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080227

EN Fr: translation not filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080528

26N No opposition filed

Effective date: 20081128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081231

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080227

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081231

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081215

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081215

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20100722 AND 20100728

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080528

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20161228

Year of fee payment: 18

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20171215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171215